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The increasing incidence and prevalence of multi-drug resistance (MDR) among contem-
porary Gram-negative bacteria represents a signiﬁcant threat to human health. Since
their discovery, β-lactam antibiotics have been a major component of the armamentarium
against these serious pathogens. Unfortunately, awide range of β-lactamase enzymes have
emerged that are capable of inactivating these powerful drugs. In the past 30 years, a major
advancement in the battle against microbes has been the development of β-lactamase
inhibitors, which restore the efﬁcacy of β-lactam antibiotics (e.g., ampicillin/sulbactam,
amoxicillin/clavulanate, ticarcillin/clavulanate, and piperacillin/tazobactam). Unfortunately,
many newly discovered β-lactamases are not inactivated by currently available inhibitors.
Is there hope? For the ﬁrst time in many years, we can anticipate the development and
introduction into clinical practice of novel inhibitors. Although these inhibitors may still not
be effective for all β-lactamases, their introduction is still welcome.This review focuses on
the novel β-lactamase inhibitors that are closest to being introduced in the clinic.
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INTRODUCTION
The ongoing dissemination of multi-drug resistant (MDR) bac-
teria is a serious threat to global health. Microbiological and
epidemiological surveys commissioned by public andprivate insti-
tutions paint a frightening portrait of the emergence of β-lactam
resistance in both the community and the hospital setting. Amajor
mechanism for antibiotic resistance among Gram-negative bacte-
ria is the production of β-lactamases. β-lactamases are enzymes
that inactivate β-lactam antibiotics by hydrolyzing the amide bond
of the β-lactam ring. β-lactamases are bacterial resistance deter-
minants that have been known formore than seventy years, yet the
details of their evolution, dissemination and hydrolytic capacity
still remains a great scientiﬁc challenge.
Two classiﬁcation systems are presently used to categorize
β-lactamases. Introduced more than thirty years ago, the Ambler
classiﬁcation systemdivides β-lactamases into four classes (A,B,C,
and D) based on their amino acid sequences (Ambler, 1980). The
Bush-Medeiros-Jacoby classiﬁcation system groups β-lactamases
according to functional properties; this classiﬁcation system uses
substrate and inhibitor proﬁles in an attempt to organize the
enzymes in ways that can be correlated with their phenotype in
clinical isolates (Bush and Jacoby, 2010). For purposes of sim-
plicity in this review, we will refer to the Ambler classiﬁcation
system.
Class A enzymes include both plasmid-mediated and
chromosomally-encoded β-lactamases that demonstrate broad-
spectra (e.g., TEM-1 and SHV-1), extended-spectra (e.g., CTX-M-
15), and carbapenemase activity (e.g., KPC-2). Class B enzymes
are metallo-β-lactamases (MBLs) which can hydrolyze penicillins,
cephalosporins, and carbapenems such as the recently described
New Delhi metallo-β-lactamase (NDM-1) found in Klebsiella
pneumoniae and Escherichia coli (Kumarasamy et al., 2010).
Class C enzymes are cephalosporinases that are chromosomally-
encoded for example the induciblePseudomonas aeruginosaAmpC
and P99 β-lactamase of Enterobacter spp., or plasmid-mediated
such as CMY-2, ﬁrst found in Escherichia coli. Class D enzymes
have a substrate preference for oxacillin and are referred to as
oxacillinases (e.g., OXA-1). Recent surveys have shown that class
D enzymes are a rapidly expanding class of β-lactamases and have
enzymes that can hydrolyze extended-spectrum cephalosporins
(e.g., OXA-10) and carbapenems (e.g., OXA-23). Several class D
enzymes are often found in non-fermenting bacteria such as P.
aeruginosa and Acinetobacter baumannii and occasionally in E.
coli and K. pneumoniae.
At present, there are three commercially available β-lactamase
inhibitors: clavulanic acid, sulbactam and tazobactam (Figure 1).
These are mechanism-based inhibitors that share a common
β-lactam structure. As a group, they are best active against most
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FIGURE 1 | Chemical structures of the clinically available β-lactamase inhibitors.
class A β-lactamases, exceptions include KPC-2 carbapenemase
and inhibitor resistant TEMs (IRTs) and SHVs. Clavulanate, sul-
bactam, and tazobactam have less effect on class C enzymes, and
are essentially inactive against class B and most class D enzymes
(Bush and Jacoby, 2010).
Encouragingly, pharmaceutical companies are aggressively
developing and bringing to market new combinations of β-
lactam antibiotics with β-lactamase inhibitors. Several of these
are now close to clinical availability. A promising new design for
β-lactamase inhibitors has been to focus on scaffolds that can
rapidly acylate a wide range of β-lactamases while minimizing
hydrolysis. This review will focus on recent data regarding the
mechanisms of inhibition of these novel agents, their antimicro-
bial activity, and the progress in their clinical trials. Speciﬁcally,
avibactam and MK-7655 are members of a new class of non-β-
lactam-β-lactamase inhibitors called diazabicyclooctanes (DBOs)
with a broader spectrum of activity than other inhibitors. Recent
modiﬁcations to boronic acid (BA) compounds have led to very
potent E. coliAmpC inhibitors that are eagerly awaited. Finally, the
discovery of a“universal”β-lactamase inhibitor has been an impor-
tant goal of both academia and the pharmaceutical industry but
has proven to be quite challenging. Emerging data show this ideal
might not be feasible and researchers investigating mechanisms
of β-lactamase inhibition will likely need to develop alternative
strategies.
DIAZABICYCLOOCTANES
AVIBACTAM
Avibactam(AVI) is anon-β-lactamcompound in the class of DBOs
(Figure 2). As aβ-lactamase inhibitor,AVI inactivates β-lactams by
a reversible fast acylation and relatively slow deacylation reaction.
Against most class A and class C β-lactamases this results in a low
turnover ratio (Ehmann et al., 2012). The β-lactamase inhibition
by AVI is mostly reversible and AVI demonstrates a half-life of
16 min for TEM-1 which closely approaches one generation time
of E. coli (Ehmann et al., 2012). Thus despite reversibly of AVI,
AVI is predicted to remain bound to TEM-1 during most of an
entire generation cycle of E. coli; thus keeping the enzyme inactive.
Unlike clavulanic acid and like sulbactam, AVI does not induce
β-lactamase production (Coleman, 2011). In addition to TEM-
1 and SHV-1, clinically important β-lactamases that are readily
inhibited by AVI include the serine carbapenemase KPC-2, the
ESBL CTX-M-15, class C β-lactamases such as the AmpC and
some class D enzymes (OXA-48).
An interesting development is the combination of this DBO
inhibitor with a number of β-lactam antibiotics that have tradi-
tionally been used to treat Gram-negative bacteria. Despite the
tendency of this class of antibiotics to select ESBLs, expanded-
spectrum cephalosporins are seen as potential partners because
they have a broader spectrum of activity. As a result, the combina-
tion of ceftazidime-AVI has potent activity against K. pneumoniae
FIGURE 2 | Chemical structures of diazabicyclooctanes.
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carrying ESBLs such as SHV-5, other ESBLs and AmpC enzymes
and also against most Klebsiella spp. harboring the KPC enzyme
(Livermore et al., 2011). Against P. aeruginosa, AVI reverses
AmpC-mediated ceftazidime resistance, reducing MICs for fully
derepressed mutants and isolates to ≤8 mg/L (Mushtaq et al.,
2010). Unfortunately, ceftazidime-AVI lacks activity against A.
baumannii and most species of anaerobic bacteria (Citron et al.,
2011; Zhanel et al., 2013).
Emerging data from clinical trials that are registered show
that ceftazidime-AVI is as effective as carbapenem therapy
for complicated urinary tract infections (UTIs) and compli-
cated intra-abdominal infections (cIAI), including those caused
by expanded-spectrum cephalosporin-resistant Gram-negative
organisms (Zhanel et al., 2013). Furthermore, a recent trial of
ceftazidime-AVI plus metronidazole in the treatment of cIAIs
found a favorable clinical response rate when compared to
meropenem (Lucasti et al., 2013).
Ceftaroline is a novel semisynthetic anti-methicillin-resistant
Staphylococcus aureus (MRSA) cephalosporin with broad-
spectrum activity. The combination of ceftaroline-AVI is active
against Enterobacteriaceae that produce KPC, various ESBLs
(CTX-M types), and AmpC (chromosomally derepressed or
plasmid-mediated enzymes), as well as against those producing
more than one of these β-lactamase types (Castanheira et al.,
2012b). However, ceftaroline’s activity against Acinetobacter spp.
and P. aeruginosa is limited. In a clinical study of diabetic
foot infections (which are often polymicrobial), ceftaroline-AVI
reduced ceftaroline MICs for strains of resistant Enterobacter spp.
and one strain of Morganella, as well as for the anaerobes Bac-
teroides fragilis and Prevotella spp. (Goldstein et al., 2013a). A
Phase 2 clinical trial comparing ceftaroline-AVI to doripenem in
adults with complicated UTIs is in progress1.
Monobactams resist hydrolysis by MBLs, thus another promis-
ing partner for AVI is aztreonam. For example, if any Enterbacte-
riaceae and P. aeruginosa strains carrying MBLs and co-produce
ESBLs or AmpC, the aztreonam would target the MBLs, while the
avibactam would inhibit the ESBLs and AmpC (Livermore et al.,
2011; Crandon et al., 2012). As such, this combination will be a
verywelcome addition to the antibiotic formulary as the safety and
efﬁcacy of aztreonam are already established in clinical practice.
MK-7655
MK-7655, a novel DBO that is structurally similar to AVI except
for an additional piperidine ring, exhibits synergy in combina-
tion with imipenem against KPC-producing K. pneumoniae and
P. aeruginosa expressing AmpC (Figure 2; Mangion et al., 2011;
Hirsch et al., 2012). Studies show that at a concentration of 4mg/L,
MK-7655 lowers imipenemMICs for Enterobacteriaceae with KPC
carbapenemases from 16–64 mg/L to 0.12–1 mg/L (Livermore
et al., 2013). Interestingly, synergy is also seen for Enterobacteri-
aceae with carbapenem resistance mediated by porin loss. Among
strains of P. aeruginosa, 4 mg/L of MK-7655 reduces the MIC of
imipenem for all isolates, except those with MBLs.
Two separate Phase 2 clinical trials of two doses (125 mg
or 250 mg) of MK-7655 plus imipenem-cilastatin vs.
1www.clinicaltrials.gov
imipenem-cilastatin alone for treatment of complicated UTIs or
cIAIs began in early 20121. Results from these trials are eagerly
awaited.
BAs
The inhibitory effects of BAs on β-lactamases have been known for
several decades. Boron forms a reversible bond with β-lactamases.
Recent studies have shown that different BAs are high afﬁnity
inhibitors of the AmpC β-lactamase of E. coli, class A β-lactamases
TEM-1, CTX-M, and SHV-1, and class C β-lactamase, ADC-7
from Acinetobacter spp. and P. aeruginosa (Drawz et al., 2010a;
Winkler et al., 2013). Many BAs are in early developmental
stages, however the progress of these compounds is rapidly
advancing.
Despite the large number of BAs in development, only one so
far is approaching clinical trials. First introduced at the 2012 Inter-
science Conference on Antimicrobial Agents and Chemotherapy,
RPX7009 is a new boron-based inhibitor being developed in com-
bination with biapenem (RPX2003; Figure 3; Castanheira et al.,
2012a; Hecker et al., 2012; Sabet et al., 2012). RPX7009 lacks direct
antibacterial activity but it does enhance the activity of biapenem
against class A carbapenemase-producing Enterobacteriaceae (e.g.,
KPC, SME, or IMI/NMC-A; Livermore and Mushtaq, 2013).
Moreover, RPX7009 lowers the MICs of biapenem against Enter-
obacteriaceae with complex β-lactamase backgrounds (AmpC or
ESBL activity) and porin losses. Unfortunately, RPX7009 does
not inhibit class B MBLs and class D carbapenemases. Against
Bacteroides and other select anaerobes, biapenem and RPX7009
demonstrates comparable activity to meropenem alone (Gold-
stein et al., 2013b). Regarding other anaerobes (Fusobacterium
spp and Prevotella) biapenem and RPX7009 are reasonable active.
Clostridia are a notable exception with the range extending up to
8 mg/L. As expected against MBL-producing Bacteroides, activity
is poor.
BAL30072 AND BAL30376
BAL30072 (Figure 4) is a novel siderophore monosulfactam
similar to aztreonam. BAL30072 demonstrates activity against
a broad range of Gram-negative bacilli including Acinetobacter
spp., P. aeruginosa, Burkholderia cepacia, and some MDR Enter-
obacteriaceae (Page et al., 2010; Russo et al., 2011; Higgins et al.,
2012). BAL30072 shows potency against carbapenem-resistant
Enterobacteriaceae including those with AmpC, ESBL, and KPC
enzymes, P. aeruginosa including most strains with MBLs and
most isolates of A. baumannii except those producing OXA-58
(Mushtaq et al., 2013). However, resistance is still observed with
the K. pneumoniae ST258 isolates carrying KPC. The addition of
meropenem to BAL30072 increases activity against certain indi-
vidual isolates of A. baumannii. BAL30072 is currently in a Phase
1 study and will likely be combined with meropenem in future
clinical development1.
In addition to BAL30072, researchers have also developed
another compoundwith broad activity against β-lactamases called
BAL30376, which combines three β-lactams: the siderophore
monobactam BAL19764, the bridged monobactam class C
β-lactamase inhibitor BAL29880 for class C cephalosporinases,
and clavulanic acid to inhibit class A enzymes (Bush andMacielag,
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FIGURE 3 | Chemical structures of a novel combination: a carbapenem (left) with a new boron-based β-lactamase inhibitor (right).
FIGURE 4 | Chemical structure of a novel siderophore monosulfactam.
2010). Further in vitro analysis and animal studies of BAL30376
will be necessary before its developmental pathway is clear.
NEW CARBAPENEMS AND BEYOND
Originally developed in the 1970s, carbapenems are among the
most broad-spectrumantibiotics in clinical use. Onemajor advan-
tage of this class of agents is their stability against hydrolysis by
many ESBLs and class C cephalosporinases. The unique property
of carbapenems that merits their inclusion in this review is their
ability to inhibit both class A and class C β-lactamases (Drawz and
Bonomo, 2010; Papp-Wallace et al., 2011) and their high afﬁnity
for the bacterial transpeptidases and carboxypeptidases that syn-
thesize the peptidoglycan-based cell wall. The carbapenem class
of β-lactams act as a “slow substrates.” Crystallographic analy-
ses show how these compounds inactivate the serine-based class A
andCenzymes by adopting unique conformations in the active site
that disfavor hydrolysis (carbonyl oxygen outside of the oxyanion
hole). The remaining parts of this sectionwill examine the promise
of some of these carbapenems that are apart from imipenem,
meropenem, ertapenem, and doripenem.
Biapenem has been available in Japan since 2002 and is cur-
rently in Phase 2 clinical study in the USA. Biapenem achieves
high concentration in respiratory tissue making it an attractive
choice for pulmonary infections (Bassetti et al., 2011). Biapenem
is hydrolyzed by MBLs and its bicyclic derivative has signiﬁcant
afﬁnity for these enzymes (Garau et al., 2005). Recent experimen-
tal evidence shows it might be possible to obtain new competitive
inhibitors of B2 MBLs by modiﬁcation of this bicyclic compound
(Gatti, 2012).
Razupenem (SMP-601; Figure 5) is a β-methyl carbapenem
with activity against MRSA, enterococci including Enterococcus
faecium and many species of Enterobacteriaceae. The activity of
razupenem is not abrogated by ESBLs but AmpC and class A car-
bapenemases seem to affect it more than ertapenem or imipenem
(Livermore et al., 2009). Pharmacodynamic data suggest razu-
penem can be dosed the same for E. coli, Proteus mirabilis and
Klebsiella spp. as for MRSA (MacGowan et al., 2011). However,
the development of razupenem has been discontinued.
LK-157 is a novel tricyclic carbapenem with potent inhibitory
activity against serine β-lactamases (Figure 5; Plantan et al., 2007).
LK-157 is a close structural analog to sanfetrinem, an oral, broad-
spectrum antibiotic whose development was stopped after Phase
2 clinical trials (Babini et al., 1998). LK-157 restores the dimin-
ished activity of β-lactam antibiotics against a number of bacterial
strains producing class A ESBLs (excluding CTX-M and KPC)
as well as class C β-lactamases (Paukner et al., 2009). Of note,
data from a rat jejunum model suggest the compound has good
bioavailability, raising the exciting possibility of an oral broad-
spectrum agent active against class A and C enzymes (Iglicar et al.,
2009).
S-649266 is a novel cephem antibiotic that promises to be
stable against MBLs2. Details are still forthcoming about this
compound, but early reports indicate S-649266 is stable against
MBL producing strains and is effective against A. baumannii,
Stenotrophomonas maltophilia, and Burkholderia spp. This is not
a new β-lactamase inhibitor, but the activity against MBLs merits
close attention.
2www.shionogi.com/pdf/RDmeeting2012.pdf
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FIGURE 5 | Chemical structures of novel β-lactams with β-lactamase inhibitor activity.
CXA-202 is the combination of ceftolozane (CXA-201)
with tazobactam (Figure 5). This formulation is targeted for
P. aeruginosa and other MDR strains and has advanced into Phase
3 trials. Per se, this is not a novel β-lactamase inhibitor but is a new
partner. The enhanced activity of the cephalosporin partner will
be examined closely as this combination represents a novel testing
paradigm in this area.
INHIBITORS OF CLASS B ENZYMES
Except for aztreonam-AVI, BAL30072, and S-649266, none of the
other aforementioned experimental β-lactams and β-lactamase
inhibitors have signiﬁcant activity against isolates expressing
MBLs. This is problematic because MBLs can spread rapidly
through mobile genetic elements, as seen with the global emer-
gence of NDM-1 (Liu et al., 2013).
The hydrolytic mechanisms of MBLs are signiﬁcantly differ-
ent from other classes of β-lactamases, requiring one or two
zinc atoms depending on the subclass. Our understanding of
MBLs is emerging as compared to the better studied class A
and C enzymes (Dubus et al., 1995; Powers and Shoichet, 2002;
Chen et al., 2006, 2009; Fisher and Mobashery, 2009). One
class of agents that appear promising against MBLs is the thiol
derivatives. Thiols, including the anti-hypertensive medication
captopril, effectively inhibit several MBLs including NDM-1 and
subclass B1, B2, and B3 enzymes (Heinz et al., 2003; King et al.,
2012). Thiol compounds utilize the same mechanisms of zinc
chelation and hydrolytic displacement. Additional clinical stud-
ies using these compounds in combination with antibiotics seem
warranted.
CHALLENGES OF INHIBITING CLASS D ENZYMES
Similar to MBLs in their diversity, class D β-lactamases are
designated OXA-type because of their ability to hydrolyze
oxacillin. Their substrate proﬁles range from narrow to broad-
spectrum, including carbapenems (Nazik et al., 2012). At present,
β-lactamase inhibitors effective against class D enzymes are not
available but promising data are emerging.
Several class D enzyme inhibitors are in development. For
instance, substituted penicillin sulfones demonstrate efﬁcacy
against a number of OXA enzymes including OXA-24/40, a
clinically relevant enzyme found in A. baumannii (Bou et al.,
2010; Drawz et al., 2010b). A compound in development, 4,7-
dichloro-1-benzothien-2-yl sulfonylaminomethyl BA (DSABA),
is the ﬁrst BA-based class D enzyme inhibitor. DSABA inhibits
class A and C enzymes as well and demonstrates synergy with
imipenem againstA. baumannii (Tan et al., 2010). A series of thio-
phenyl oxime phosphonate β-lactamase inhibitors with potency
against OXA-24/40 have also been discovered (Tan et al., 2011). Of
interest, one compound reduces the MIC of imipenem against
a highly imipenem-resistant strain of OXA-24/40 producing
A. baumannii.
CHOOSING THE RIGHT PARTNER ANTIBIOTIC AND THE
CHALLENGES AHEAD
Determining the ideal β-lactam for a given β-lactamase inhibitor
and deﬁning the ratio of the inhibitor to that β-lactam is a complex
process. Indeed, it has been suggested that several considerations
should be taken into account: (1) the ability of the inhibitor to
protect the β-lactam ring from hydrolysis by key target enzymes;
(2) the quantity of inhibitor needed to protect the β-lactam ring;
(3) the feasibility and stability of the formulation; (4) pharma-
cokinetic and dosing parameters; and (5) cost (Shlaes, 2013).
However, it is difﬁcult to use standard pharmacokinetic and phar-
macodynamic indices with inhibitors because they have weak to
no intrinsic antimicrobial activity and they are usually partnered
with an active antimicrobial agent. Mathematical modeling is one
approach to these challenges. Usingmathematical systems in phar-
macodynamic models may help deﬁne regimens for inhibitors to
prevent false labeling of a drug as ineffective because of dosing
failures (Bush, 2012).
The report of a single isolate of K. pneumoniae producing
a serine carbapenemase, a MBL, an ESBL and a plasmid-
encoded AmpC carbapenemase underscores the challenge of
using β-lactam antibiotics in the clinical setting (Pournaras
et al., 2010). Treating this kind of pathogen with a β-lactam
will likely require one with high stability to many common
β-lactamases (e.g., aztreonam), together with two or more
β-lactamase inhibitors that inhibit MBLs and serine β-lactamases.
An example is the triple compoundBAL30376 (Bush andMacielag,
2010; Livermore et al., 2010; Page et al., 2011). In addition to
exerting a bactericidal effect against a wide range of β-lactamase-
producing organisms including strains that were resistant to
other β-lactams (except for KPC carbapenemases); BAL30376
is also relatively refractory toward selection of resistant mutants
(Page et al., 2011).
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FUTURE PERSPECTIVE
The majority of the compounds reviewed in this paper are
in preclinical stages and (with the exception of AVI and
MK-7655) are years away from availability. Thus, the pace
of drug development must increase in order to meet the
Infectious Diseases Society of America’s goal of 10 new sys-
temic drugs to treat infections caused by resistant bacteria by
2020 (Infectious Diseases Society of America, 2010;Boucher et al.,
2013). The lack of drug candidates potentially active againstMBLs
is a great concern. For infections caused by bacteria harboring
MBLs, treatment options are limited to polymyxins, tigecycline,
and fosfomycin. Moreover, new β-lactamases are reported world-
wide with alarming frequency, which continues to put strain
on our existing antibiotic armamentarium (Lamoureaux et al.,
2013). While novel β-lactamase inhibitors with new mechanisms
of action provide substantial advances compared to currently
available agents, incremental advances to existing classes are also
valuable and should be encouraged (Page and Heim, 2009). The
long quest for a universal β-lactamase inhibitor is becoming
increasing quixotic withmore pragmatic approaches, such as drug
combinations, now a leading paradigm.
A plethora of strategies to invigorate drug development have
been recently proposed (Infectious Diseases Society of America,
2012; Spellberg et al., 2013). These include conducting superi-
ority and organism-speciﬁc clinical trials, transparency through
public reporting of antibiotic usage tied to reimbursement, using
molecular techniques for diagnostic conﬁrmation of antibiotic
indications, and investigating agents that modify host immune
responses to pathogens to circumvent resistance selection.We also
suggest that attention be given to alternative agents with activity
against β-lactamases. Additional research studies are warranted
especially since MBLs are important drivers of pan-resistant phe-
notypes.We remain positive in our outlook as the progress to date
merits conﬁdence that new drugs will be available very soon.
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